Table 2.
Nanoparticles in AAA treatment.
| Nanoparticles | Targets | Component | Drugs loaded | Model | Administration | Detailed application |
|---|---|---|---|---|---|---|
| EL-PEG-PLA | Elastase laminae | Elastin antibody modified PEGylated poly | BB-94 | CaCl2-induced rats, Systemic calcifaction rats, aherosclerotic plaque created in ApoE−/− mice | Injection once | Targeted delivery of BB-94 loaded EL-PEG-PLA NPs (8). |
| PLGA NPs | MMP | Coencapsulate with doxycycline and SPION, and Cationic-functionalized PLGA NPs. | Doxycycline, Statins | AngII-infusion mice, C57BL/6 mice underwent transient elastase perfusion | Implanted once; oral daily; | Inhibit MMP enzymatic function (62) and activities, and facilitate the preservation of the elastic matrix (63, 64). |
| HA-o-NP | VSMCs | HA loaded PLGA | HA | CaCl2-induced mice | adenoviral gene transfer | Enhanced deposition of elastin matrix and increased LOX activity (65). |
| Drug -loaded NPs | SMCs | TGF-β1-loaded NPs, Doxycycline-loaded NPs | TGF-β1, Doxycycline | In vitro | Increased elastin content and matrix assembly (66). | |
| PEG-b-PBLG | AAA lesion | Alexa647-labeled NPs | Rapamycin | Porcine pancreatic elastase mice | IV route at 14-day and 21-day | Treating already developed AAA (67). |
| NP-incorporating rapamycin | AAA lesion | Poly(ethyleneglycol)-shelled nanoparticles incorporating rapamycin | Rapamycin | Porcine pancreatic elastase mice | IV route at 14-day and 21-day | Treat already developed AAA (67). |
| ROS-NPs | AAA lesion | PEG-phospholipid, oxidation-responsive β-cyclodextrin derivative. | Rapamycin | Porcine pancreatic elastase rats | IV route at 7-day | ROS-NPs can trigger the release of payload to control inflammation and aneurysm growth (68). |
DIR-PLA, PLA-NPs to load 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DIR) dyes; DMAB, didodecyldimethyl ammonium bromide; DSPE-PEG, PEG-phospholipid; EL-PEG-PLA NPs, Elastin antibody-modified PEGylated poly PLA nanoparticles; LOX, lysyl oxidase; OxbCD, oxidation-responsive β-cyclodextrin derivative; PEG-b-PBLG, poly (ethylene glycol)-b-poly (γ-benzyl L-glutamate); pHEMA, biotinylated poly (2- hydroxyethyl methacrylate); RGD, Arginine-Glycine-Aspartic acid; HA, Hyaluronic acid; VSMCs, Vascular smooth muscle cells.